---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-040447"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-06-03T20:43:17+00:00"
generated_at: "2026-06-03T21:04:51.051853+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acumen stockholders elect three Class II directors, approve equity plan

## Summary
- Elected Golumbeski (37.3M for), Porter (30.9M for), Stoppel (30.8M for) as Class II directors.
- Ratified Ernst & Young as auditor for FY 2026: 56.9M for, 113k against.
- Approved Amended and Restated 2021 Equity Incentive Plan: 30.7M for, 6.6M against, 19.7M broker non-votes.
- Turnout: 57.1M of 72.2M shares (78.99%) present or represented at annual meeting.

## SEC filing metadata
- accession: 0001628280-26-040447
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-06-03T20:43:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/abos-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-040447
- JSON: https://secwatch.observer/filing/0001628280-26-040447.json
- Plain text: https://secwatch.observer/filing/0001628280-26-040447.txt

## Key facts
- Shareholder Votes
  Acumen Pharmaceuticals, Inc. shareholders approved Election of three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal No. 1: The stockholders elected three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes George Golumbeski, Ph.D. 37,305,711 68,820 19,676,925
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm
- Shareholder Votes
  Acumen Pharmaceuticals, Inc. shareholders approved Approval of the Company's Amended and Restated 2021 Equity Incentive Plan. at the 2026-06-03 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal No. 3 : The stockholders approved the Company’s Amended and Restated 2021 Equity Incentive Plan. The votes were cast as follows: Votes For Votes Against Abstained Broker Non-Votes Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan 30,731,776 6,618,621 24,134 19,676,925
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm
- Shareholder Votes
  Acumen Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 56,934,900 113,074 3,482
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.